Royce & Associates LP Entrada Therapeutics, Inc. Transaction History
Royce & Associates LP
- $9.35 Billion
- Q3 2025
A detailed history of Royce & Associates LP transactions in Entrada Therapeutics, Inc. stock. As of the latest transaction made, Royce & Associates LP holds 345,507 shares of TRDA stock, worth $2.93 Million. This represents 0.02% of its overall portfolio holdings.
Number of Shares
345,507
Previous 223,251
54.76%
Holding current value
$2.93 Million
Previous $1.5 Million
33.53%
% of portfolio
0.02%
Previous 0.02%
Shares
2 transactions
Others Institutions Holding TRDA
# of Institutions
117Shares Held
27.9MCall Options Held
13.7KPut Options Held
14K-
Baker Bros. Advisors LP New York, NY4.87MShares$41.2 Million0.23% of portfolio
-
Mpm Asset Management LLC Cambridge, MA4.38MShares$37.1 Million56.82% of portfolio
-
5 Am Venture Management, LLC San Francisco, CA4.26MShares$36.1 Million16.56% of portfolio
-
Black Rock Inc. New York, NY1.69MShares$14.3 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.6MShares$13.6 Million0.0% of portfolio
About Entrada Therapeutics, Inc.
- Ticker TRDA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 31,368,500
- Market Cap $266M
- Description
- Entrada Therapeutics, Inc., a biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its endosomal escape vehicle platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. The company's lead product candidate is ENTR-601-44, which is in precli...